STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

NCT07213570 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: standard second line treatment, at discretion of the investigator
DRUG: Regorafenib (BAY73-4506)

Sponsor

National Cancer Institute, Naples